Fungal infections, often overshadowed by bacterial threats, are developing resistance to treatments, contributing to what ...
In the period spanning 2017-2021, a mere 12 new antibiotics entered the market, with only one capable of targeting all the ...
Fosmanogepix is a first-in-class antifungal treatment candidate with a novel mechanism of action. It is available in intravenous and oral formulations and has been evaluated for efficacy and safety in ...
The world faces a growing crisis in antifungal resistance, with fungal infections causing millions of deaths annually.